Israeli Pharma Firm NeuroRx Completes SPAC Merger at $1.5B Valuation
The firm's two main medicines include a drug for COVID-19-related respiratory failure and another focusing on suicidal bipolar depression.
May 31, 2021
Sponsored by the Asper Foundation and Reichman University
